Why Catalyst Pharmaceuticals Inc. [CPRX] Stock Can Run Back to New Highs Quicker Than You Think

Catalyst Pharmaceuticals Inc. [CPRX] stock is down -0.87 while the S&P 500 has risen 0.09% on Monday, 12/07/20. While at the time of this article, CPRX ATR is sitting at 0.16, with the beta value at 1.57. This stock’s volatility for the past week remained at 4.52%, while it was 4.49% for the past 30-day period. CPRX has fallen -$0.03 from the previous closing price of $3.43 on volume of 0.53 million shares.

On 9, November 2020, Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update. According to news published on Yahoo Finance, – Firdapse® Third Quarter Net Revenues of $29.2 Million.

Analyst Birdseye View:

The most recent analyst activity for Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] stock was on September 07, 2018, when it was Resumed with an Overweight rating from Piper Jaffray. On October 05, 2016, Piper Jaffray Upgrade an Overweight rating. On April 26, 2016, Piper Jaffray Downgrade a Neutral rating and decreased its price target from $6 to $1. On September 30, 2014, ROTH Capital Reiterated a Buy rating and increased its price target to $6. On September 16, 2014, ROTH Capital Reiterated a Buy rating and boosted its amount target on this stock to $5. On September 15, 2014, H.C. Wainwright Reiterated a Buy rating and boosted its target amount on this stock from $5 to $13. On October 21, 2013 Aegis Capital Reiterated a Buy rating and elevated its amount target to $5.50.

In the past 52 weeks of trading, this stock has oscillated between a low of $2.55 and a peak of $5.28. Right now, according to Wall Street analyst the average 12-month amount target is $7.40. At the most recent market close, shares of Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] were valued at $3.40.

FUNDAMENTAL ANALYSIS

Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] most recently reported quarterly sales of 29.32 billion, which represented growth of -5.20%. This publicly-traded organization’s revenue is $1,346,136 per employee, while its income is $419,412 per employee. This company’s Gross Margin is currently 86.00%, its Operating Margin is 34.40%, its Pretax Margin is +32.66, and its Net Margin is +31.16. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at 36.89, 46.06, 45.67 and 45.84 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 1.07 and the whole liability to whole assets at 0.84. It shows enduring liability to the whole principal at 0.73 and enduring liability to assets at 0.01 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.35 points at 1st support level, the second support level is making up to 3.26. But as of 1st resistance point, this stock is sitting at 3.57 and at 3.71 for 2nd resistance point.

Catalyst Pharmaceuticals Inc. [CPRX] reported its earnings at $0.41 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at $0.1/share signifying the difference of 0.31 and 310.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were $0.09 calling estimates for $0.08/share with the difference of 0.01 depicting the surprise of 12.50%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] is 7.90. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.92. Now if looking for a valuation of this stock’s amount to sales ratio it’s 3.89, it’s amount to book ratio is 4.42 and showing 5.10 of P/E (TTM) ratio.

Insider Stories

The most recent insider trade was by O’Keeffe Charles B, Director, and it was the purchase of 7000.0 shares on Sep 30. MCENANY PATRICK J, the President and CEO, completed a purchase of 15000.0 shares on Sep 30.